. 2010 Dec 6;29(3):272–278. doi: 10.1200/JCO.2010.29.1609

Table 3.

Randomized, Controlled Trials Evaluating PCI

Study	No. of Patients	Primary Therapy	Dose (Gy)	CNS Metastases			1-Year Survival (%)	Median Survival (months)
Study	No. of Patients	Primary Therapy	Dose (Gy)	Observation (%)	PCI (%)	P	1-Year Survival (%)	Median Survival (months)
VALG 1981¹	281	RT only(all NSCLC)	20 (2 Gy × 10)	13	6	.038	NA	7-8
MDACC 1984³	97	Multimodality (all NSCLC)	30 (3 Gy × 10)	27	4	.002	NA	NA
RTOG 1991²	187	RT only (nonsquamous)	30 (3 Gy × 10)	19	9	.10	13 (2-year)	8
RTOG 2009 (this study)	340	Multimodality (all NSCLC)	30 (2 Gy × 15)	18	7.7	.004	75	25

Abbreviations: PCI, prophylactic cranial irradiation; VALG, Veterans Affairs Lung Group; RT, radiation therapy; NSCLC, non–small-cell lung cancer; NA, not applicable; MDACC, MD Anderson Cancer Center; RTOG, Radiation Treatment Oncology Group.